Progyny, Inc. (NASDAQ:PGNY) Given Average Rating of “Hold” by Brokerages

Progyny, Inc. (NASDAQ:PGNY) has been assigned a consensus recommendation of “Hold” from the twelve brokerages that are covering the company, MarketBeat.com reports. Seven investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $27.73.

Several research firms have recently commented on PGNY. JPMorgan Chase & Co. reduced their price target on shares of Progyny from $31.00 to $22.00 and set an “overweight” rating on the stock in a research report on Thursday, September 19th. Leerink Partners reduced their target price on Progyny from $25.00 to $21.00 and set a “market perform” rating on the stock in a research report on Thursday, September 19th. Cantor Fitzgerald reiterated an “overweight” rating and set a $25.00 price target on shares of Progyny in a report on Tuesday, October 1st. Truist Financial reduced their price objective on shares of Progyny from $33.00 to $26.00 and set a “buy” rating on the stock in a report on Thursday, September 19th. Finally, Jefferies Financial Group lowered their target price on shares of Progyny from $31.00 to $24.00 and set a “buy” rating for the company in a research note on Thursday, September 19th.

Institutional Investors Weigh In On Progyny

Large investors have recently bought and sold shares of the stock. Quarry LP raised its holdings in shares of Progyny by 1,900.0% in the 2nd quarter. Quarry LP now owns 880 shares of the company’s stock valued at $25,000 after purchasing an additional 836 shares in the last quarter. TFC Financial Management Inc. acquired a new stake in Progyny in the first quarter valued at $42,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Progyny during the 2nd quarter worth about $44,000. Financial Management Professionals Inc. acquired a new position in shares of Progyny during the 1st quarter worth about $52,000. Finally, Mendota Financial Group LLC acquired a new position in shares of Progyny during the 3rd quarter worth about $56,000. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Progyny Stock Performance

NASDAQ:PGNY opened at $15.45 on Monday. Progyny has a one year low of $13.93 and a one year high of $42.08. The stock has a market cap of $1.47 billion, a PE ratio of 25.33, a P/E/G ratio of 1.52 and a beta of 1.43. The stock has a 50 day moving average price of $19.34 and a 200 day moving average price of $25.21.

Progyny (NASDAQ:PGNY) last issued its earnings results on Tuesday, August 6th. The company reported $0.17 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.17. The business had revenue of $304.09 million during the quarter, compared to the consensus estimate of $305.32 million. Progyny had a return on equity of 11.97% and a net margin of 5.54%. The company’s revenue for the quarter was up 8.8% on a year-over-year basis. During the same period last year, the company earned $0.15 EPS. As a group, analysts predict that Progyny will post 0.64 earnings per share for the current fiscal year.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.